Mar 20 |
Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
|
Mar 8 |
Immunic to reveal promising MS treatment data in two poster presentations at ACTRIMS Forum 2024
|
Mar 7 |
Immunic to Participate in Investor and Scientific Conferences in March
|
Feb 29 |
Immunic And 2 Other Stocks Under $2 Insiders Are Buying
|
Feb 29 |
Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
|
Feb 24 |
Immunic Inc (IMUX) Reports Year-End 2023 Financial Results
|
Feb 23 |
Immunic, Inc. (NASDAQ:IMUX) Q4 2023 Earnings Call Transcript
|
Feb 22 |
Immunic, Inc. (IMUX) Q4 2023 Earnings Call Transcript
|
Feb 22 |
Immunic reports successful 2023 and prepares for key 2025 milestones
|
Feb 22 |
Immunic GAAP EPS of -$2.11 misses by $1.60
|